Metoclopramide Hcl Noridem (Metoclopramide Hydrochloride Monohydrate)

The drug blocks dopamine D2 receptors in the chemoreceptor trigger zone and the gastrointestinal tract, while also antagonizing serotonin 5‑HT3 receptors and stimulating 5‑HT4 receptors. This dual action speeds up stomach emptying and reduces the brain’s perception of nausea, providing symptomatic relief.

The appropriate dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal benefit while minimizing potential adverse effects.

Safety data for Metoclopramide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after evaluating the individual circumstances.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Metoclopramide differs from many antiemetics by combining dopamine antagonism with serotonin modulation, giving it both anti‑nausea and gastro‑prokinetic properties. Unlike pure 5‑HT3 antagonists, it also promotes gastric emptying, which can be advantageous in conditions like gastroparesis, but it carries a distinct risk profile for extrapyramidal reactions.

Store the injectable product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the vial or ampoule is sealed until use to maintain sterility and potency.

The medication is supplied for parenteral use and can be given by intramuscular injection or intravenous infusion. Administration technique, rate, and dilution are determined by the prescribing clinician and should follow standard aseptic procedures and institutional protocols.

Serious adverse events include extrapyramidal symptoms such as acute dystonia, tardive dyskinesia with long‑term use, and neuroleptic malignant syndrome, a rare but life‑threatening condition. Prompt recognition and discontinuation of the drug are essential if any of these reactions occur.

Patients with known hypersensitivity to metoclopramide or any component of the formulation should avoid it. Caution is also advised for individuals with a history of seizure disorders, severe depression, or those taking interacting medications such as antipsychotics, MAO inhibitors, or other central nervous system depressants.